An analysis of FDA-approved drugs for neurological disorders

Michael S. Kinch

Research output: Contribution to journalShort surveypeer-review

23 Scopus citations


Neuroscience remains a great challenge and opportunity in terms of new drug discovery and development. An assessment of FDA-approved new molecular entities (NMEs) reveals a low steady rate of new FDA approvals, which is interrupted by two bursts in activity, first in the 1950s and then in the 1990s. These trends are reflected in the approvals for NMEs targeting multiple indications in this field, including seizure, Parkinson's disease and neuromuscular disorders. The majority of drugs target ion channels or G-protein-coupled receptors (GPCRs) but the mechanistic basis for many NMEs remains unclear or controversial. These trends could suggest future opportunities for success in a crucial field with considerable unmet needs.

Original languageEnglish
Pages (from-to)1040-1043
Number of pages4
JournalDrug Discovery Today
Issue number9
StatePublished - Sep 9 2015


Dive into the research topics of 'An analysis of FDA-approved drugs for neurological disorders'. Together they form a unique fingerprint.

Cite this